SARS-CoV-2 Spike-pseudovirus Based Neutralization Assay
Creative Biolabs, as a leading biomedical CRO in the industry, has successfully helped thousands of researchers complete the development of drugs and vaccines. These achievements are inseparable from our excellent R&D platform and experienced technicians. In the development of COVID-19 drugs and vaccines, one of the most important evaluation indicators is to detect the neutralization ability of the therapeutics to SARS-CoV-2 virus. To this end, we have developed the pseudovirus corresponding to SARS-CoV-2 and provided related pseudovirus-based neutralization test services.
The ability of vaccines or drugs to neutralize viruses is an important sign of their efficacy in preventing or treating viral diseases. Under normal circumstances, the vaccine or drug can be directly incubated with living virus in vitro, and then the virus' ability to infect cells can be observed to evaluate its virus-neutralizing ability. However, for the highly infectious SARS-CoV-2, operations related to living viruses must be performed under BSL-3 conditions, which greatly limits the development process of COVID-19 vaccines and drugs. Pseudoviruses have the proteins necessary for living viruses to infect cells, but lack the nucleic acid of the virus and cannot replicate in the body. Therefore, they are ideal tools for studying the ability of vaccines and drugs to neutralize viruses.
SARS-CoV-2 has four structural proteins: spike protein (S), membrane protein (M), envelope protein (E), and nucleocapsid protein (N). Among them, S protein is related to virus attachment and entry into target cells, which is considered to be a key protein to start the process of virus infection. Besides, during SASR-CoV-2 infection, S protein plays an important role in inducing protective humoral and cellular immune responses. Therefore, S protein has become the most attractive target for the development of SARS-CoV-2 vaccines and drugs.
The S protein contains two subunits, S1 and S2. The RBD of the S1 subunit binds to the ACE2 receptor on the surface of human cells to mediate the fusion of the virus with the host cell membrane and enter the cell. Creative Biolabs uses HIV-1 containing a luciferase reporter gene as a backbone plasmid, and co-transfects 293 cells with a plasmid expressing the SARS-CoV-2 spike protein to package a spike-pseudovirus with SARS-CoV-2 spike expressing on its surface and containing luciferase reporter gene inside. In combination with our proprietary ACE2-CHO Clonal Cell-line, Creative Biolabs has successfully evaluated the neutralizing ability of antibodies and serum and is glad to offer this service to our clients all over the world.
If you are interested in our SARS-CoV-2 spike-pseudovirus based neutralization assay, please do not hesitate to contact us for more details.
Fig.1 Principle of spike-pseudovirus based neutralization assay.For Research Use Only. We do not provide services or products directly for patients.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.